Joinn Laboratories(China)Co.,Ltd.

SHSE:603127 Stock Report

Market Cap: CN¥12.0b

Joinn Laboratories(China)Co.Ltd Valuation

Is 603127 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603127 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603127 (CN¥17.68) is trading above our estimate of fair value (CN¥6.6)

Significantly Below Fair Value: 603127 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603127?

Key metric: As 603127 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 603127. This is calculated by dividing 603127's market cap by their current revenue.
What is 603127's PS Ratio?
PS Ratio6.1x
SalesCN¥2.12b
Market CapCN¥12.04b

Price to Sales Ratio vs Peers

How does 603127's PS Ratio compare to its peers?

The above table shows the PS ratio for 603127 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.4x
603108 Shanghai Runda Medical Technology
1.4xn/aCN¥11.6b
688131 Shanghai Haoyuan Chemexpress
3.7x21.0%CN¥7.8b
688046 GemPharmatech
7.8x21.7%CN¥5.3b
688710 Shanghai Innostar Biotechnology
4.9xn/aCN¥5.5b
603127 Joinn Laboratories(China)Co.Ltd
6.1x12.1%CN¥12.0b

Price-To-Sales vs Peers: 603127 is expensive based on its Price-To-Sales Ratio (6.1x) compared to the peer average (4.4x).

Price to Sales Ratio vs Industry

How does 603127's PS Ratio compare vs other companies in the CN Life Sciences Industry?

0 CompaniesPrice / SalesEstimated GrowthMarket Cap
No more companies available in this PS range
603127 6.1xIndustry Avg. 4.9xNo. of Companies6PS03.26.49.612.816+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 603127 is expensive based on its Price-To-Sales Ratio (6.1x) compared to the CN Life Sciences industry average (4.9x).

Price to Sales Ratio vs Fair Ratio

What is 603127's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603127 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.1x
Fair PS Ratio3.5x

Price-To-Sales vs Fair Ratio: 603127 is expensive based on its Price-To-Sales Ratio (6.1x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603127 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥17.68
CN¥15.60
-11.8%
37.4%CN¥23.00CN¥6.90n/a6
Nov ’25CN¥16.96
CN¥15.15
-10.7%
35.6%CN¥23.00CN¥6.90n/a6
Oct ’25CN¥18.05
CN¥14.82
-17.9%
33.4%CN¥21.00CN¥6.90n/a6
Sep ’25CN¥14.09
CN¥15.93
+13.0%
31.7%CN¥21.50CN¥8.00n/a6
Aug ’25CN¥15.52
CN¥16.06
+3.5%
32.1%CN¥21.50CN¥8.00n/a6
Jul ’25CN¥13.35
CN¥18.73
+40.3%
20.9%CN¥22.40CN¥10.00n/a7
Jun ’25CN¥15.23
CN¥18.66
+22.5%
20.8%CN¥22.40CN¥10.00n/a7
May ’25CN¥16.39
CN¥18.66
+13.8%
20.8%CN¥22.40CN¥10.00n/a7
Apr ’25CN¥18.86
CN¥22.09
+17.1%
31.7%CN¥33.00CN¥10.00n/a7
Mar ’25CN¥18.23
CN¥22.98
+26.0%
28.8%CN¥33.00CN¥11.70n/a7
Feb ’25CN¥16.58
CN¥24.44
+47.4%
27.1%CN¥33.00CN¥11.70n/a7
Jan ’25CN¥23.71
CN¥29.22
+23.2%
18.6%CN¥35.00CN¥16.90n/a7
Dec ’24CN¥26.44
CN¥30.33
+14.7%
19.4%CN¥38.07CN¥16.90n/a8
Nov ’24CN¥26.39
CN¥30.66
+16.2%
19.6%CN¥38.07CN¥16.90CN¥16.968
Oct ’24CN¥23.82
CN¥31.09
+30.5%
14.9%CN¥38.07CN¥22.60CN¥18.058
Sep ’24CN¥23.35
CN¥33.30
+42.6%
24.1%CN¥50.71CN¥22.60CN¥14.098
Aug ’24CN¥27.66
CN¥37.55
+35.7%
24.6%CN¥50.71CN¥26.15CN¥15.528
Jul ’24CN¥29.21
CN¥41.38
+41.6%
31.6%CN¥65.71CN¥26.15CN¥13.358
Jun ’24CN¥33.28
CN¥43.38
+30.4%
29.5%CN¥65.71CN¥26.15CN¥15.237
May ’24CN¥35.35
CN¥43.86
+24.1%
28.8%CN¥65.71CN¥26.15CN¥16.397
Apr ’24CN¥37.40
CN¥48.99
+31.0%
27.8%CN¥65.71CN¥26.66CN¥18.865
Mar ’24CN¥41.54
CN¥54.15
+30.4%
27.6%CN¥71.43CN¥26.66CN¥18.235
Feb ’24CN¥45.69
CN¥54.69
+19.7%
25.0%CN¥71.43CN¥30.13CN¥16.585
Jan ’24CN¥41.72
CN¥50.93
+22.1%
29.2%CN¥71.43CN¥30.13CN¥23.716
Dec ’23CN¥42.53
CN¥50.93
+19.8%
29.2%CN¥71.43CN¥30.13CN¥26.446
Nov ’23CN¥44.31
CN¥56.22
+26.9%
19.2%CN¥71.43CN¥38.26CN¥26.395

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.19

7D

-2.6%

1Y

13.6%